Compugen (CGEN) to Release Earnings on Monday

Compugen (NASDAQ:CGEN) will likely be announcing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.05 per share and revenue of $14.2960 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 2, 2026 at 8:30 AM ET.

Compugen Price Performance

Shares of CGEN opened at $1.74 on Monday. The company’s fifty day moving average price is $1.76 and its 200-day moving average price is $1.64. Compugen has a 1-year low of $1.13 and a 1-year high of $2.38.

Institutional Trading of Compugen

A number of hedge funds have recently modified their holdings of CGEN. Franklin Resources Inc. purchased a new position in Compugen during the second quarter valued at approximately $56,000. Jane Street Group LLC boosted its position in Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after purchasing an additional 359,785 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 34,045 shares during the period. Two Sigma Investments LP grew its stake in shares of Compugen by 10.6% during the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 18,929 shares during the period. Finally, Raymond James Financial Inc. increased its holdings in shares of Compugen by 51.0% during the 3rd quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 34,215 shares in the last quarter. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Wall Street Analyst Weigh In

CGEN has been the topic of several research analyst reports. HC Wainwright initiated coverage on Compugen in a research note on Wednesday, January 7th. They set a “buy” rating and a $4.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of Compugen from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $4.00.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.